Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

30.40USD
19 Sep 2014
Price Change (% chg)

$-0.18 (-0.59%)
Prev Close
$30.58
Open
$30.76
Day's High
$30.84
Day's Low
$30.26
Volume
15,414,650
Avg. Vol
5,617,144
52-wk High
$32.96
52-wk Low
$27.88

PFE.N

Chart for PFE.N

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.69
Market Cap (Mil.): $192,762.20
Shares Outstanding (Mil.): 6,340.86
Dividend: 0.26
Yield (%): 3.42

Financials

  PFE.N Industry Sector
P/E (TTM): 19.18 32.84 33.70
EPS (TTM): 1.59 -- --
ROI: 6.80 18.11 17.35
ROE: 13.38 18.82 18.21
Search Stocks

Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

(Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

12 Sep 2014

UPDATE 1-Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

Sept 12 (Reuters - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

12 Sep 2014

UPDATE 1-Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

Sept 12 - Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.

12 Sep 2014

BRIEF-Pfizer, Ranbaxy win dismissal of lawsuit by "direct purchaser" plaintiffs over generic Lipitor

Sept 12 - * U.S. judges grants Pfizer Inc Ranbaxy Laboratories Ltd

12 Sep 2014

UPDATE 2-SAC's Martoma gets 9 years prison for insider trading

(Adds details from court hearing, comment from Martoma spokesman)

08 Sep 2014

Zoetis granted conditional license by USDA for PEDv vaccine

CHICAGO - Zoetis Inc has received a conditional license from the U.S. Department of Agriculture for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.

03 Sep 2014

Weaker healthcare stocks weigh on European equities

* Bid target AstraZeneca falls; CEO says "back to normal"

02 Sep 2014

European equities dip as healthcare stocks weaken

* Bid target AstraZeneca falls; CEO says "back to normal"

02 Sep 2014

Early data suggest Sanofi, Regeneron drug may halve heart risk

* Good news for new PCSK9 drug class but needs confirmation

31 Aug 2014

FTSE inches higher, Tesco slumps after profit warning

LONDON, Aug 29 - Britain's top share index ended slightly higher on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks outpacing a sharp decline in retail stocks after another profit warning by Tesco .

29 Aug 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $107.99 +0.64
Novartis AG (NOVN.VX) CHF88.30 -0.15
Merck & Co., Inc. (MRK.N) $60.49 +0.18
Roche Holding Ltd. (ROG.VX) CHF283.20 -0.10
Abbott Laboratories (ABT.N) $43.59 -0.10
Bayer AG (BAYGn.DE) €95.41 -2.28
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €88.76 +0.30
AstraZeneca plc (AZN.L) 4,578.50p +42.00
GlaxoSmithKline plc (GSK.L) 1,449.00p +12.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks